Skip to content

COVID-19 Response

Customer Service: 866-788-9007

CLINICIAN PORTAL | CRF LOGIN

COVID-19 Response

Customer Service: 866-788-9007

CLINICIAN PORTAL | CRF LOGIN

Customer Service: 866-788-9007

CLINICIAN PORTAL | CRF LOGIN

Company
Products
Research & Development
- Our Approach
Investors
Scientific Publications
Resources

LATEST NEWS: Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry

Company
Products
Research & Development
- Our Approach
Investors
Scientific Publications
Resources

Analysis of RFS and DMFS for combined DecisionDx-Melanoma and SLN predicted outcomes

By Chris Otte / August 28, 2017

Post navigation

← Previous Media

Connect with Us

Company

About Us
Our History
Leadership
- Board of Directors
Licenses
Careers
Contact Us

Products

Cutaneous Melanoma
Cutaneous SCC
- DecisionDx-SCC
Uveal Melanoma
Barrett’s Esophagus
- TissueCypher
Mental Health
- IDgenetix

Research & Development

Our Approach

Latest News & Publications

Press Releases
Scientific Publications
Email Alerts

Resources

Healthcare Professionals
- Login/Register
- Order A Test
Patients

Copyright © 2023 Castle Biosciences, Inc. | All Rights Reserved

Privacy Policy
Terms of Use
Contact Us